支气管炎治疗市场 - 全球产业规模、份额、趋势、机会和预测，按药物类别、类型、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球支气管炎治疗市值为 83.6 亿美元，预计到 2030 年将达到 95.6 亿美元，预测期内复合年增长率为 5.21%。支气管炎是一种呼吸系统疾病，其特征是支气管发炎，通常由病毒或细菌感染引起。全球支气管炎治疗市场涵盖旨在控制和缓解支气管炎症状的药品、疗法和医疗设备。医学研究的不断进步导致了创新支气管炎治疗方案的发展。根据美国国家生物中心 2022 年 2 月的一篇题为「急性支气管炎」的文章，估计每年有 5% 的普通人群会经历一次急性支气管炎，导致每年超过 1000 万人次就诊。因此，支气管炎盛行率的不断上升推动了治疗需求，进而推动了市场的成长。

製药公司正在投资研发新药物和新疗法，为患者提供更好的治疗效果。这些医学突破透过提供更有效、更有针对性的治疗方法正在扩大市场。

旨在推广流感等呼吸道感染疫苗接种的公共卫生措施正在降低支气管炎的风险。增强对预防措施的认识，例如适当的手部卫生和避免接触刺激物，有助于减少支气管炎病例。随着这些措施的实施，重点转向现有病例的管理和治疗，进一步促进支气管炎治疗市场的发展。城市化和更忙碌、紧张的生活方式导致了吸烟习惯的增加。随着人们搬到城市并面临现代生活的压力，有些人选择吸烟作为一种应对机制。都市生活方式使得不良习惯更普遍，导致支气管炎发生率更高，因此治疗需求也更大。

主要市场驱动因素

支气管炎盛行率高

主要市场挑战

抗生素抗药性

主要市场趋势

改变生活方式和吸烟习惯

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球支气管炎治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类别（抗生素、消炎药、支气管扩张药、其他）
  • 依类型（急性支气管炎、慢性支气管炎）
  • 按最终用户（医院药房、零售药房、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美支气管炎治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲支气管炎治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区支气管炎治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲支气管炎治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲支气管炎治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• AstraZeneca PLC
• Novartis AG
• GSK PLC
• Dr. Reddy's Laboratories Ltd
• Sanofi SA
• Boehringer Ingelheim International GmbH
• Pfizer Inc
• Melinta Therapeutics Inc
• Lupin Ltd
• Cadila Pharmaceuticals Ltd

第 15 章：策略建议

第16章 调査会社について・免责事项

Global Bronchitis Treatment Market was valued at USD 8.36 Billion in 2024 and is expected to reach USD 9.56 Billion by 2030 with a CAGR of 5.21% during the forecast period. Bronchitis is a respiratory condition characterized by inflammation of the bronchial tubes, often resulting from viral or bacterial infections. The global bronchitis treatment market encompasses pharmaceuticals, therapies, and medical devices aimed at managing and alleviating the symptoms of bronchitis. Continuous advancements in medical research have led to the development of innovative bronchitis treatment options. According to a February 2022 article by the National Center for Bio, titled "Acute Bronchitis," it is estimated that 5% of the general population experiences an episode of acute bronchitis annually, resulting in over 10 million office visits each year. Consequently, the increasing prevalence of bronchitis is driving the demand for treatment, which in turn is fueling market growth.

Pharmaceutical companies are investing in creating new medications and therapies that offer better outcomes for patients. These medical breakthroughs are expanding the market by providing more effective and targeted treatment approaches.

Public health initiatives aimed at promoting vaccination against respiratory infections like influenza are reducing the risk of bronchitis. Increased awareness about preventive measures, such as proper hand hygiene and avoiding exposure to irritants, is contributing to a reduction in bronchitis cases. As these measures gain traction, the focus shifts to the management and treatment of existing cases, further boosting the bronchitis treatment market. Urbanization and the adoption of more hectic and stressful lifestyles contribute to an increase in smoking habits. As people move to urban areas and face the pressures of modern life, some turn to smoking as a coping mechanism. The urban lifestyle fosters environments where unhealthy habits are more prevalent, leading to a higher incidence of bronchitis and, consequently, greater demand for treatment.

Key Market Drivers

High Prevalence of Bronchitis

Bronchitis, a common respiratory condition characterized by the inflammation of the bronchial tubes, poses a significant health concern worldwide. The global bronchitis treatment market is experiencing substantial growth, and one of the primary driving forces behind this expansion is the high prevalence of bronchitis.

The high prevalence of bronchitis means that a substantial number of individuals are affected by this condition. Bronchitis can be acute or chronic and may result from various factors such as respiratory infections, smoking, and exposure to environmental pollutants. With millions of people being diagnosed with bronchitis each year, there is a consistent and growing demand for effective treatment options. The world's population is aging, with a significant proportion of individuals aged 65 and older. This demographic group is more susceptible to respiratory conditions, including chronic bronchitis. As the elderly population continues to expand, the market for bronchitis treatment is expected to grow in tandem.

Rapid urbanization has led to increased exposure to air pollution, a known risk factor for bronchitis. In densely populated urban areas with high levels of air pollution, the prevalence of bronchitis is notably elevated. As urbanization persists globally, so does the demand for bronchitis treatment, driven by the adverse effects of polluted air on respiratory health. Lifestyle factors play a significant role in the development of bronchitis. Smoking, both active and passive, remains a prominent risk factor for bronchitis. However, public health campaigns and increasing awareness about the dangers of smoking are driving more individuals to seek treatment for bronchitis symptoms. This heightened awareness is boosting the market as more patients are diagnosed and treated. In February 2022, the United States Food and Drug Administration (USFDA) granted approval to Lupin Limited's generic version of Brovana (arformoterol tartrate) for the treatment of bronchoconstriction in individuals with chronic obstructive pulmonary disease (COPD). The active ingredient in Brovana is a bronchodilator, which works by relaxing and widening the airways, thereby reducing bronchoconstriction.

Access to healthcare services is expanding in many parts of the world, enabling individuals to seek diagnosis and treatment for bronchitis more readily. The increasing availability of healthcare facilities and professionals is instrumental in driving market growth, as individuals are more likely to receive proper care and treatment.

Key Market Challenges

Antibiotic Resistance

Antibiotic resistance is an escalating concern in the treatment of bronchitis, particularly bacterial bronchitis. The widespread use of antibiotics, often as a first-line treatment, has led to the emergence of resistant bacterial strains, making standard therapies less effective. Overprescription, patient non-compliance with prescribed courses, and the use of broad-spectrum antibiotics when narrow-spectrum options may suffice contribute to this growing issue. As resistant bacteria become more prevalent, healthcare providers face increasing difficulties in managing infections, leading to prolonged illness durations and higher risks of complications.

Antibiotic resistance limits the availability of effective medications, forcing the medical community to seek alternative treatments, such as combination therapies or newer, more expensive antibiotics. These alternatives may not always be accessible or affordable, particularly in low-resource settings. In some cases, treatment failure due to resistance can result in hospitalizations and increased healthcare costs. Resistant strains can spread within communities and healthcare facilities, exacerbating the problem.

Efforts to combat antibiotic resistance include promoting antimicrobial stewardship programs, educating healthcare professionals and patients on responsible antibiotic use, and encouraging the development of novel therapeutics. Greater emphasis on preventive measures, such as vaccinations and public awareness campaigns, can also help reduce the reliance on antibiotics. By implementing stricter guidelines on antibiotic prescription and usage, healthcare systems can work toward mitigating the long-term consequences of resistance, ensuring that bronchitis and other bacterial infections remain treatable in the future.

Key Market Trends

Changing Lifestyles and Smoking Habits

Bronchitis, a common respiratory condition characterized by inflammation of the bronchial tubes, is often linked to lifestyle choices and smoking habits. As individuals increasingly adopt unhealthy lifestyles and continue to smoke, the global bronchitis treatment market is experiencing significant growth. Smoking remains one of the most significant risk factors for developing bronchitis. Tobacco smoke contains harmful chemicals that irritate the airways and increase susceptibility to respiratory infections. Despite ongoing efforts to curb smoking, a substantial portion of the global population continues to smoke or be exposed to secondhand smoke.

Changing lifestyles are often accompanied by increased awareness of the health risks associated with smoking. Public health campaigns and educational initiatives have raised awareness about the dangers of tobacco use. Smokers are increasingly seeking help to quit, and this heightened awareness drives individuals to seek medical assistance and treatment for bronchitis symptoms. Even non-smokers can develop bronchitis due to exposure to secondhand smoke. In households or public spaces where smoking is prevalent, individuals who do not smoke themselves may still face the health consequences of inhaling tobacco smoke. The rising awareness of these risks has led to greater demand for bronchitis treatment.

Chronic bronchitis, often linked to long-term smoking, is a persistent form of the condition that requires ongoing treatment. Individuals with chronic bronchitis experience recurrent symptoms and require regular medical attention. As the number of individuals with chronic bronchitis grows due to smoking habits, the market for bronchitis treatment expands accordingly. The demand for bronchitis treatment has spurred pharmaceutical companies to invest in research and development. New medications and therapies are continually being developed to provide more effective and targeted treatment options for bronchitis patients. As these innovations become available, they enhance the overall market for bronchitis treatment.

Regional Insights

North America hold a dominant position, and this trend is expected to persist throughout the forecasted period. Specifically, within North America, the United States has established a significant presence in the bronchitis treatment market. This prominence can be attributed to various factors, including the rising incidence of bronchitis cases, a growing prevalence of smoking among the younger population, and a surge in strategic initiatives undertaken by key market players. United States received diagnoses related to chronic obstructive pulmonary disease (COPD), emphysema, or chronic emphysema. Given the association between COPD and bronchitis, there is a substantial demand for bronchitis treatment in the country, contributing significantly to market expansion. several market participants are actively pursuing strategic endeavors, further bolstering market growth. As an illustration, in June 2021, Lupin introduced Arformoterol, a generic inhalation product designed for the treatment of chronic bronchitis, into the United States market. These developments are expected to catalyze the creation of more such products and their subsequent approvals for bronchitis treatment in the nation, thus fostering continued market growth in the foreseeable future.

Key Market Players

• AstraZeneca PLC
• Novartis AG
• GSK PLC
• Dr. Reddy's Laboratories Ltd
• Sanofi SA
• Boehringer Ingelheim International GmbH
• Pfizer Inc
• Melinta Therapeutics Inc
• Lupin Ltd
• Cadila Pharmaceuticals Ltd

Report Scope:

In this report, the Global Bronchitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bronchitis Treatment Market, By Class of Drugs:

• Antibiotics
• Anti-inflammatory Drugs
• Bronchodilator
• Others

Bronchitis Treatment Market, By Type:

• Acute Bronchitis
• Chronic Bronchitis

Bronchitis Treatment Market, By End User:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Bronchitis Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bronchitis Treatment Market.

Available Customizations:

Global Bronchitis Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bronchitis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Class of Drugs (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Others)
  • 5.2.2. By Type (Acute Bronchitis, Chronic Bronchitis)
  • 5.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Bronchitis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Class of Drugs
  • 6.2.2. By Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bronchitis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Class of Drugs
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Bronchitis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Class of Drugs
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Bronchitis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Class of Drugs
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End User

7. Europe Bronchitis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Class of Drugs
  • 7.2.2. By Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bronchitis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Class of Drugs
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Bronchitis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Class of Drugs
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Bronchitis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Class of Drugs
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End User
  • 7.3.4. France Bronchitis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Class of Drugs
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Bronchitis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Class of Drugs
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Bronchitis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Class of Drugs
  • 8.2.2. By Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Bronchitis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Class of Drugs
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Bronchitis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Class of Drugs
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Bronchitis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Class of Drugs
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Bronchitis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Class of Drugs
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Bronchitis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Class of Drugs
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End User

9. South America Bronchitis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Class of Drugs
  • 9.2.2. By Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bronchitis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Class of Drugs
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Bronchitis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Class of Drugs
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Bronchitis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Class of Drugs
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Bronchitis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Class of Drugs
  • 10.2.2. By Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bronchitis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Class of Drugs
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Bronchitis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Class of Drugs
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Bronchitis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Class of Drugs
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. AstraZeneca PLC
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. GSK PLC
• 14.4. Dr. Reddy's Laboratories Ltd
• 14.5. Sanofi SA
• 14.6. Boehringer Ingelheim International GmbH
• 14.7. Pfizer Inc
• 14.8. Melinta Therapeutics Inc
• 14.9. Lupin Ltd
• 14.10. Cadila Pharmaceuticals Ltd

15. Strategic Recommendations

16. About Us & Disclaimer